Jasper Therapeutics, Inc. (JSPR) Stock Price, Financial Report, & Fundamental Analysis

Strength

Analysis	#
Net Income Growth JSPR has had growing net income for the last 2 years
Price to Book (PBV) Ratio Undervalued price-to-book. JSPR stock price is under 1x the price-to-book value.
Debt-Equity Ratio (DER) JSPR equity is higher than it's debt.

Weakness

Analysis	#
Market Cap Small market capitalization. Market capitalization is less than 2bn USD
Revenue Growth JSPR has never had growing revenue.
Net Income JSPR never has positive net income for 2 years.
Dividend Yield JSPR has low dividend yield (0%).
Return of Assets JSPR has low return of asset (-5.77%).
Return of Equity JSPR has low return of equity (-5.59%).
Revenue JSPR never has positive revenue for 2 years.
Return of Invested Capital JSPR has low ROIC.

Competitors

Financial statements are written records that convey the business activities and the financial performance of a company. Financial statements include the balance sheet, income statement, and statement of cash flow.

Income Statement

Also known as the profit and loss (P&L) statement or the statement of revenue and expense, the income statement primarily focuses on the company’s revenue and expenses during a particular period.

Cashflow Statement

A cash flow statement is a financial statement that provides aggregate data regarding all cash inflows a company receives from its ongoing operations and external investment sources. It also includes all cash outflows that pay for business activities and investments during a given period.

Free Cash Flow

-36,106,000 USD

Dividend

Financial Ratios

CEO

CEO Name

Management

About Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.

Additional Information

Company name

Jasper Therapeutics, Inc.

Symbol

NASDAQ:JSPR

Exchange

NASDAQ Capital Market

Industry

Biotechnology

Sector

Healthcare

Address

2200 Bridge Parkway
Redwood City
CA
US
94065

Website

https://jaspertherapeutics.com